SHORT MINI-FUTURE - GILEAD SCIENCES | Market Closed - Deutsche Boerse AG 11:22:04 17/05/2024 pm IST | ||
| 3.4 EUR | +0.29% |
|
| Current month | -7.61% | ||
| 1 month | -2.58% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
GILEAD SCIENCES, INC.
Latest news about GILEAD SCIENCES, INC.
More news
| Date | Price | Change |
|---|---|---|
| 17/24/17 | 3.4 | +0.29% |
| 16/24/16 | 3.39 | -0.29% |
| 15/24/15 | 3.4 | -1.16% |
| 14/24/14 | 3.44 | -0.29% |
| 13/24/13 | 3.45 | -3.63% |
Delayed Quote Deutsche Boerse AG
Last update May 17, 2024 at 11:22 pm IST
More quotesStatic data
| Product type | Knock-Out mit Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | GILEAD SCIENCES, INC. |
| Issuer | 
Vontobel
|
| WKN | VU0E92 |
| ISIN | DE000VU0E929 |
| Date issued | 01/12/2022 |
| Strike | 104.4 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 1.98 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 3.73 € |
|---|---|
| Lowest since issue | 1.59 € |
Company Profile
Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows:
- sale of drugs (98.9%): for the treatment of HIV (63% of net sales), COVID-19 (20.4%), hepatitis C virus (6.6%), hepatitis B virus (3.6%) and other (6.4%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV);
- other (1.1%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products.
Net sales are distributed geographically as follows: the United States (69.2%), Europe (16.4%) and other (14.4%).
Sector
-
Consensus: Gilead Sciences, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
67.72
USD
Average target price
82.93
USD
Spread / Average Target
+22.46%
- Stock Market
- Certificates
- Certificat
